Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Nuhpro

Italian “Food as Medicine” company selling patented pre/probiotic functional foods for digestive disorders, intolerances and diabetes.

Rimini, Italy, EuropeAgri & FoodTech, Functional foods / “Food as Medicine”
Stage
Pre-seedAI integrated
Product
On the marketFirst customers
Funding raised
$130Kdisclosed
Founded
20233 years ago
Founders
2Claudia, Chiara
Global score
4.8Grade DRank 48 of 151

Overview

Italian FoodTech building a “Food as Medicine” platform through functional food brands (SWEE-THY, PRO+PRO, FREEDA) targeting digestive disorders, intolerances and diabetes.

Traction

First customers

Functional food brands (SWEE-THY, PRO+PRO, FREEDA) sold B2C and B2B (Dealroom); Nourish Awards 2024 finalist and Vitafoods Europe finalist (most innovative nutraceutical product); Pegasus Tech Ventures recognition shown on the site; no sales figures published.

Market

Functional foods

Functional foods for gut health and glycaemic control are bought by consumers with chronic digestive issues or diabetes, increasingly on advice from clinicians and nutritionists. Growth is driven by microbiome science, ageing populations and the shift from treatment to dietary prevention. Retail and pharmacy shelf space is crowded, so evidence-backed claims and professional recommendation channels are the main levers of differentiation. Under EU rules, health claims require substantiation, which favours brands that can generate clinical evidence.

Addressable market

2025
$380B
2030
$530B
+6.91% a year

Functional foods: ~$380bn in 2025 (Cervicorn, CAGR 6.9%) — an upper bound; the digestive/diabetes niche addressed is much smaller.

Customers

Consumers with digestive disorders, food intolerances or diabetes; pharmacies, health retailers and B2B food partners

Who signs the cheque

End consumers (B2C) and retail / distribution buyers (B2B)

Geographies

  • Italy
  • Europe

Drivers

  • Rising prevalence of diabetes and digestive disorders
  • Microbiome science legitimising pre/probiotics
  • Clinician-led lifestyle and nutrition prescribing

Headwinds

  • Strict EU health-claim substantiation
  • Crowded shelf and big-brand competition
  • Limited capital (€120K pre-seed)

Cervicorn Consulting values functional foods at ~$380bn in 2025 (CAGR 6.9% 2025-34); publisher range ~$260–400bn; 2030 extrapolated ~$530bn; the digestive/diabetes niches are a fraction of it. — Broad segment: the functional foods market serves as an upper bound; the niche actually addressed is much smaller.

Scalability 5/10. Physical food products: distribution, supply chain and health claims must be validated country by country.

Market source: cervicornconsulting.com

Technology

Category

Functional food formulation (nutraceuticals)

AI integratedMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

Patented formulations combine prebiotics and probiotics, including a heat-resistant probiotic strain that survives processing. An AI personalised-nutrition platform is in development to complement the products.

Moat

Moderate: patents on formulations and a heat-resistant probiotic; brand and evidence base still thin.

Differentiation

Condition-specific brands (SWEE-THY, PRO+PRO, FREEDA) versus generic probiotic or free-from products.

Integration points

  • Clinician / nutritionist prescribing platforms
  • Pharmacy and e-commerce channels
  • Personalised-nutrition apps

Depends on

  • Clinical evidence for health claims
  • Probiotic strain supply
  • Retail and pharmacy listings

Use of AI

AI-powered personalized nutrition platform in development, complementing the functional foods.

Product in detail

Patented formulations combining prebiotics and probiotics (including a heat-resistant probiotic); AI nutrition platform in development.

Business

Model
Sale of branded functional food products, B2C and B2B.
Revenue logic
Unit product margin; no sales figures published.
Go-to-market
Direct and B2B distribution in Italy, supported by industry awards (Nourish, Vitafoods finalist).

Next milestones

  1. Human data showing probiotic survival and effect in the gut
  2. A professional prescribing channel
  3. Seed round to fund distribution beyond Italy

Key risks

  • Health-claim substantiation
  • Undercapitalisation
  • Weak differentiation against large brands

Opportunities

4 found in the network

Concrete moves for Nuhpro inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Co-development 1
  • Investors 2

Distribution1

A channel or customer base to reach together

Embed Nuhpro products in IKI’s prescribed lifestyle programmes

IKI lets clinicians prescribe personalised lifestyle-medicine programmes; nutrition is a core component but IKI does not sell food. Listing Nuhpro's condition-specific products as prescribable items gives Nuhpro a clinician channel in Spain and IKI a tangible, monetisable programme component.

25%confidence

Evidence from the records

  • “lets healthcare professionals prescribe personalized lifestyle medicine programs”
  • “Professional subscriptions on sale on the website”
  • “targeting digestive disorders, intolerances and diabetes”
If it works
A referral / affiliate listing inside IKI programmes and first sales in Spain.
First step
Propose to IKI Health a product-catalogue integration pilot with an affiliate commission.

Co-development1

An integration or joint product

Prove in-gut probiotic survival with Microvitality’s sampling capsule

Nuhpro's key claim is a heat-resistant probiotic, but the decisive question — does it reach and act in the small intestine — is hard to measure non-invasively. Microvitality's capsule samples the small intestine in situ and is approved for human use, so a joint study would give Nuhpro claim-grade evidence and Microvitality a first paying study sponsor.

35%confidence

Evidence from the records

  • “Patented formulations combining prebiotics and probiotics (including a heat-resistant probiotic)”
  • “Health claims”
  • “Capsule validated in 3 large animal models and NSR/IRB approved for human use”
If it works
A small human sampling study that substantiates Nuhpro's gut claims and becomes Microvitality's first commercial use case.
First step
Hold a call between both CEOs to scope a 10–20 volunteer sampling protocol and its cost.

Investors2

A fund whose thesis fits

Target CDP Venture Capital for an Italian seed round

CDP Venture Capital invests from pre-seed to Series A in Italy and is already cited in Nuhpro's ecosystem; it also backed network member Mon5 through Forward Factory. That gives two warm paths to an Italian anchor investor.

30%confidence

Evidence from the records

  • “ecosystem cited: EIT Food, Le Village, CesenaLab, La Gemma Venture, CDP, Novonesis”
  • “Primo Capital (lead), Forward Factory (CDP Venture Capital), GDA Invest SCSp”
If it works
An Italian anchor ticket to fund distribution and clinical evidence.
First step
Ask Mon5's founders for an intro to their Forward Factory / CDP contact.

Convert the Pegasus recognition into a follow-up investment conversation

Pegasus Tech Ventures, organiser of the Startup World Cup, already recognised Nuhpro and invested in network member Coachbot through the SWC. The Grand Finale is the natural moment to request a diligence meeting.

20%confidence

Evidence from the records

  • “Pegasus Tech Ventures recognition shown on the site”
  • “Startup World Cup (Pegasus Tech Ventures)”
If it works
A diligence meeting and potential seed ticket.
First step
Request a meeting slot with the Pegasus investment team during the SWC Grand Finale week.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Italy's national VC institution, investing pre-seed to Series A and running accelerators such as Forward Factory (MON5, Proxima Robotics).

Italian "Food as Medicine" functional foods sold B2C and B2B: Italian consumer-health innovation at pre-seed.

40%confidence

Evidence from the records

  • “Functional foods / “Food as Medicine””
  • “Italy”

Korean food group's corporate investor; the only recorded deal is Yo-Kai Express's Series A, an automated ramen vending company.

Italian 'food as medicine' brands for digestive disorders and diabetes, aligned with health-positioned food portfolios.

35%confidence

Evidence from the records

  • “Functional foods / “Food as Medicine””
  • “Agri & FoodTech”
First step
Explore Korean distribution or licensing with Pulmuone.

European VC that joined FRESH 32's seed (sustainable oral care); thesis and ticket are undocumented.

Italian functional food brands sold B2C and B2B: European consumer health products like FRESH 32.

25%confidence

Evidence from the records

  • “Functional foods / “Food as Medicine””
  • “Pre-seed”
Intro path
FRESH 32 (AYMO portfolio, network peer)
First step
Ask FRESH 32 for an intro to AYMO.

Milan-based Italian venture manager that led OT-security company MON5's 2026 capital increase.

Italian functional-food brands; Italian but consumer food is far from MON5's industrial profile.

20%confidence

Evidence from the records

  • “Functional foods / “Food as Medicine””
  • “Italy”
First step
Low priority; pitch only if Primo confirms consumer interest.

Investment analysis

4.8D

Grade D

Rank 48 of 151

Disruption4.0/10
Business model4.0/10
Market7.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early and weakly differentiated.

Disruption

4/10

“Food as Medicine” functional foods: a known category.

Business model

4/10

Brands sold B2C and B2B, volumes not published.

Market

7/10

Score 7/10: TAM $380bn → base 7; scalability 5/10 (0); no commercial presence in ≥2 countries yet (0).

Risk

7/10

Lower is better

High risk: little capital, regulated health claims.

Strengths

  • Products on sale
  • Industry awards

Risks

  • Limited capital
  • Health claims

Funding

$130K, disclosed
  1. 2025

    pre-seed€120,000

    not disclosed (ecosystem cited: EIT Food, Le Village, CesenaLab, La Gemma Venture, CDP, Novonesis)

  2. non précisée

    grant (Dealroom, amount not public)not disclosed

    not disclosed

Amount used in the study. €120K pre-seed; undisclosed grant and 2026 seed round in preparation excluded.

Note. €120K (pre-seed 2025); seed round in preparation for 2026

Official site: NuHpro srl, Rimini; founders not named on the site. Product lines: Junior Nutrition, Gut Health, Sports Nutrition; PRO+PRO Longevity and NUHPRO AI in development. Funding conflict: one directory (Prospeo) states “no funding round”, contrary to the €120K pre-seed in 2025 — existing value kept for lack of a primary source. SWC 2026 qualification not found (absent from the WMF 2026 Bologna results; only a “Pegasus Tech Ventures” recognition appears on the site): reg left empty.

Team

  • Claudia Guidi

    Founder & CEO (product formulation)

    Product formulator with 10+ years of experience in food intolerances and functional nutrition.

  • Chiara Guidi

    Co-founder (food science & R&D)

    Food technologist specializing in nutritional science and ingredient research; Claudia's sister.

Sources

Identification confidence
high
Founding year: 2023
2023 (according to a secondary directory, not confirmed)
  1. 1nuhpro.com/
  2. 2app.dealroom.co/companies/nuhpro
  3. 3prospeo.io/c/nuhpro
  4. 4en.wemakefuture.it/next/startup-competition/final/2026/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet